Table 2.

The association between the degree of HPV 16m and risk of being diagnosed with CIN 2+

Cases vs. non-cases
Model 1aModel 2bModel 3c
Risk factorsOR (95% CI)POR (95% CI)POR (95% CI)P
Age, y
 <231.000.211.000.151.000.14
 ≥231.43 (0.82–2.54)1.53 (0.86–2.74)1.54 (0.87–2.75)
Race
 Caucasian American1.000.931.000.991.000.93
 African American1.03 (0.55–1.92)1.00 (0.53–1.88)0.97 (0.52–1.82)
Education
 High school education or higher1.000.881.000.911.000.89
 Less than high school education1.05 (0.55–1.96)0.96 (0.50–1.81)1.05 (0.55–1.96)
Waist circumference, cm
 ≤881.000.251.000.371.000.32
 >880.73 (0.41–1.26)0.78 (0.44–1.35)0.76 (0.43–1.31)
Smoking status
 Never smoker1.000.231.000.221.000.24
 Ever smoker1.51 (0.76–3.05)1.54 (0.77–3.12)1.51 (0.76–3.05)
Lifetime number of sexual partners
 ≤51.000.231.000.191.000.19
 >50.72 (0.41–1.24)0.69 (0.39–1.20)0.69 (0.40–1.20)
Use of oral/hormone contraceptive
 Non-user1.000.991.000.921.000.90
 User1.00 (0.47–2.22)0.96 (0.45–2.14)1.05 (0.49–1.14)
Vitamin C, μg/mL
 <15.131.000.421.000.761.000.53
 ≥15.131.25 (0.73–2.13)1.09 (0.63–1.88)1.19 (0.69–2.04)
Total carotene, μg%
 <87.931.000.651.000.611.000.65
 ≥87.930.88 (0.50–1.53)0.86 (0.49–1.51)0.88 (0.50–1.54)
HPV 16m, %
 Promoter site
  <111.000.02
  ≥110.52 (0.30–0.88)
 Enhancer site
  <101.00<0.01
  ≥100.37 (0.21–0.64)
 Promoter and enhancer site combined
  <111.00<0.01
  ≥110.45 (0.26–0.78)
  • aModel with HPV 16m of the promoter site.

  • bModel with HPV 16m of the enhancer site.

  • cModel with HPV 16m of the promoter and enhancer combined.